Kopion Asset Management LLC raised its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 8.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,159 shares of the company's stock after purchasing an additional 44,516 shares during the period. Certara accounts for about 4.6% of Kopion Asset Management LLC's investment portfolio, making the stock its 12th largest position. Kopion Asset Management LLC owned approximately 0.37% of Certara worth $5,942,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Certara by 751.8% during the first quarter. GAMMA Investing LLC now owns 71,726 shares of the company's stock worth $7,245,000 after buying an additional 63,305 shares during the last quarter. Versant Capital Management Inc grew its holdings in Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the last quarter. Kera Capital Partners Inc. bought a new position in shares of Certara in the first quarter valued at approximately $139,000. Mackenzie Financial Corp acquired a new stake in shares of Certara in the fourth quarter worth $17,852,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Certara by 16.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,574 shares of the company's stock worth $2,807,000 after buying an additional 37,870 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have weighed in on CERT shares. Stephens reissued an "overweight" rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. JMP Securities restated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Finally, Robert W. Baird raised their target price on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.
Check Out Our Latest Stock Analysis on CERT
Certara Stock Up 4.7%
Shares of NASDAQ CERT traded up $0.54 during mid-day trading on Wednesday, hitting $12.00. The company had a trading volume of 636,390 shares, compared to its average volume of 1,344,329. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a 50-day simple moving average of $11.91 and a two-hundred day simple moving average of $11.80. The company has a market capitalization of $1.95 billion, a PE ratio of -60.00, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44. Certara, Inc. has a one year low of $8.64 and a one year high of $17.76.
Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 earnings per share. On average, equities analysts expect that Certara, Inc. will post 0.28 EPS for the current year.
Certara Company Profile
(
Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
